A study has revealed that fondaparinux, a synthetic inhibitor of coagulation factor Xa, is a promising treatment option for patients with acute coronary syndromes. Mehta et al. performed a combined ...
The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback